BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 21243928)

  • 1. In vivo and in vitro immunological changes induced by a short course of grass allergy immunotherapy tablets.
    Panizo C; Cimarra M; González-Mancebo E; Vega A; Senent C; Martín S
    J Investig Allergol Clin Immunol; 2010; 20(6):454-62. PubMed ID: 21243928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunologic effects and tolerability profile of in-season initiation of a standardized-quality grass allergy immunotherapy tablet: a phase III, multicenter, randomized, double-blind, placebo-controlled trial in adults with grass pollen-induced rhinoconjunctivitis.
    Reich K; Gessner C; Kroker A; Schwab JA; Pohl W; Villesen H; Wüstenberg E; Emminger W
    Clin Ther; 2011 Jul; 33(7):828-40. PubMed ID: 21741092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis.
    Durham SR; Yang WH; Pedersen MR; Johansen N; Rak S
    J Allergy Clin Immunol; 2006 Apr; 117(4):802-9. PubMed ID: 16630937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allergy immunotherapy tablet: Grazax® for the treatment of grass pollen allergy.
    Senna GE; Calderon M; Milani M
    Expert Rev Clin Immunol; 2011 Jan; 7(1):21-7. PubMed ID: 21162646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunological changes during sublingual immunotherapy with standardized quality grass allergen tablets.
    Malling HJ; Lund L; Ipsen H; Poulsen L
    J Investig Allergol Clin Immunol; 2006; 16(3):162-8. PubMed ID: 16784009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunoglobulin E and G antibody profiles to grass pollen allergens during a short course of sublingual immunotherapy.
    Aberer W; Hawranek T; Reider N; Schuster C; Sturm G; Kränke B
    J Investig Allergol Clin Immunol; 2007; 17(3):131-6. PubMed ID: 17583098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis.
    Dahl R; Stender A; Rak S
    Allergy; 2006 Feb; 61(2):185-90. PubMed ID: 16409194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy with a Phleum pratense allergen extract induces an immune response to a grass-mix allergen extract.
    Martínez-Cócera C; Sastre J; Cimarra M; Quirce S; Fernández-Rivas M; Enríquez-Matas A; Rodríguez-Alvarez M; Martín S
    J Investig Allergol Clin Immunol; 2010; 20(1):13-9. PubMed ID: 20232769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose sublingual immunotherapy with single-dose aqueous grass pollen extract in children is effective and safe: a double-blind, placebo-controlled study.
    Wahn U; Klimek L; Ploszczuk A; Adelt T; Sandner B; Trebas-Pietras E; Eberle P; Bufe A;
    J Allergy Clin Immunol; 2012 Oct; 130(4):886-93.e5. PubMed ID: 22939758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of serum IgG4 antibodies specific to grass pollen allergen components in the follow up of allergic patients undergoing subcutaneous and sublingual immunotherapy.
    Rossi RE; Monasterolo G; Coco G; Silvestro L; Operti D
    Vaccine; 2007 Jan; 25(5):957-64. PubMed ID: 17045368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical efficacy of 300IR 5-grass pollen sublingual tablet in a US study: the importance of allergen-specific serum IgE.
    Cox LS; Casale TB; Nayak AS; Bernstein DI; Creticos PS; Ambroisine L; Melac M; Zeldin RK
    J Allergy Clin Immunol; 2012 Dec; 130(6):1327-34.e1. PubMed ID: 23122534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunologic effect and tolerability of intra-seasonal subcutaneous immunotherapy with an 8-day up-dosing schedule to 10,000 standardized quality-units: a double-blind, randomized, placebo-controlled trial.
    Pfaar O; Wolf H; Klimek L; Schnitker J; Wüstenberg E
    Clin Ther; 2012 Oct; 34(10):2072-81. PubMed ID: 23063373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of seasonal allergic rhinoconjunctivitis with a once-daily SQ-standardized grass allergy immunotherapy tablet.
    Nelson H; Lehmann L; Blaiss MS
    Curr Med Res Opin; 2012 Jun; 28(6):1043-51. PubMed ID: 22502864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet.
    Durham SR; Emminger W; Kapp A; Colombo G; de Monchy JG; Rak S; Scadding GK; Andersen JS; Riis B; Dahl R
    J Allergy Clin Immunol; 2010 Jan; 125(1):131-8.e1-7. PubMed ID: 20109743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years.
    Dahl R; Kapp A; Colombo G; de Monchy JG; Rak S; Emminger W; Riis B; Grønager PM; Durham SR
    J Allergy Clin Immunol; 2008 Feb; 121(2):512-518.e2. PubMed ID: 18155284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sustained 3-year efficacy of pre- and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen-induced rhinoconjunctivitis.
    Didier A; Worm M; Horak F; Sussman G; de Beaumont O; Le Gall M; Melac M; Malling HJ
    J Allergy Clin Immunol; 2011 Sep; 128(3):559-66. PubMed ID: 21802126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and tolerability of an SQ-standardized GRAss ALlergy immunotherapy tablet (GRAZAX®) in a real-life setting for three consecutive seasons - the GRAAL trial.
    Wessel F; Chartier A; Meunier JP; Magnan A
    Clin Drug Investig; 2012 Jul; 32(7):451-63. PubMed ID: 22594491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of specific sublingual immunotherapy with SQ standardized grass allergen tablets in children.
    Ibañez MD; Kaiser F; Knecht R; Armentia A; Schöpfer H; Tholstrup B; Bufe A
    Pediatr Allergy Immunol; 2007 Sep; 18(6):516-22. PubMed ID: 17680910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Grass tablet sublingual immunotherapy downregulates the TH2 cytokine response followed by regulatory T-cell generation.
    Suárez-Fueyo A; Ramos T; Galán A; Jimeno L; Wurtzen PA; Marin A; de Frutos C; Blanco C; Carrera AC; Barber D; Varona R
    J Allergy Clin Immunol; 2014 Jan; 133(1):130-8.e1-2. PubMed ID: 24290282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical efficacy of microencapsulated timothy grass pollen extract in grass-allergic individuals.
    TePas EC; Hoyte EG; McIntire JJ; Umetsu DT
    Ann Allergy Asthma Immunol; 2004 Jan; 92(1):25-31. PubMed ID: 14756461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.